Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance.

[1]  J. George,et al.  Overcoming treatment resistance in cancer: Current understanding and tactics. , 2017, Cancer letters.

[2]  Xinchun Chen,et al.  Uridine homeostatic disorder leads to DNA damage and tumorigenesis. , 2016, Cancer letters.

[3]  Yu Cao,et al.  A phosphomimetic mutant of RelA/p65 at Ser536 induces apoptosis and senescence: An implication for tumor‐suppressive role of Ser536 phosphorylation , 2016, International journal of cancer.

[4]  R. Savai,et al.  CRISPR-Cas9-based target validation for p53-reactivating model compounds , 2015, Nature chemical biology.

[5]  Yu Cao,et al.  Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice , 2014, Clinical Cancer Research.

[6]  G. Selivanova,et al.  Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro , 2013, Clinical Cancer Research.

[7]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[8]  J. Roh,et al.  The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. , 2012, Cancer letters.

[9]  S. Markwell,et al.  AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker , 2012, International journal of cancer.

[10]  R. Breitling,et al.  Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents , 2012, Cell Death and Disease.

[11]  D. Cao,et al.  AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. , 2011, Toxicology and applied pharmacology.

[12]  Lin-Feng Chen,et al.  Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. , 2010, Cellular signalling.

[13]  L. Szekely,et al.  Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. , 2010, Cancer research.

[14]  C. Van Waes,et al.  Nuclear NF-κB p65 Phosphorylation at Serine 276 by Protein Kinase A Contributes to the Malignant Phenotype of Head and Neck Cancer , 2009, Clinical Cancer Research.

[15]  V. Grinkevich,et al.  Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. , 2009, Cancer cell.

[16]  Vasilis Vasiliou,et al.  Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.

[17]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.

[18]  A. Jetten,et al.  NF-κB-dependent Transcriptional Activation in Lung Carcinoma Cells by Farnesol Involves p65/RelA(Ser276) Phosphorylation via the MEK-MSK1 Signaling Pathway* , 2008, Journal of Biological Chemistry.

[19]  Krishna Rao,et al.  Aldo-keto Reductase Family 1 B10 Affects Fatty Acid Synthesis by Regulating the Stability of Acetyl-CoA Carboxylase-α in Breast Cancer Cells* , 2008, Journal of Biological Chemistry.

[20]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[21]  Jun Ma,et al.  Aldo–keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention , 2007, International journal of cancer.

[22]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[23]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[24]  Mazhar Adli,et al.  IKK-i/IKKϵ Controls Constitutive, Cancer Cell-associated NF-κB Activity via Regulation of Ser-536 p65/RelA Phosphorylation* , 2006, Journal of Biological Chemistry.

[25]  Thomas J. Smith,et al.  Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[27]  M. Schmitz,et al.  Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to , 2004, The Journal of biological chemistry.

[28]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[29]  Z. Duan,et al.  Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. , 2004, Molecular cancer therapeutics.

[30]  K. Scotto.  Transcriptional regulation of ABC drug transporters , 2003, Oncogene.

[31]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[32]  Zhe-Sheng Chen,et al.  Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). , 2002, Cancer research.

[33]  M. Blagosklonny,et al.  P53: An ubiquitous target of anticancer drugs , 2002, International journal of cancer.

[34]  P. Hainaut,et al.  Genotoxic and non-genotoxic pathways of p53 induction. , 2001, Cancer letters.

[35]  J. Crown,et al.  The taxanes: an update , 2000, The Lancet.

[36]  M. Burt,et al.  Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  Sheung Tat Fan,et al.  Identification and Characterization of a Novel Human Aldose Reductase-like Gene* , 1998, The Journal of Biological Chemistry.

[38]  L. O’Driscoll,et al.  Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance , 1997, International journal of cancer.

[39]  P. Baeuerle,et al.  The p65 subunit is responsible for the strong transcription activating potential of NF‐kappa B. , 1991, The EMBO journal.

[40]  M. Merville,et al.  Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation , 2005 .

[41]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[42]  R. Wurm,et al.  Normal tissue radiosensitivity--how important is it? , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).